AMBULATORY INFUSION  ·  SPECIALTY PHARMACY  ·  THERAPY MANAGEMENT
Home  /  Therapy Areas  /  Gastroenterology
Therapy Area

Gastroenterology.

Conditions we treat

  • Crohn’s disease
  • Ulcerative colitis
  • Microscopic colitis (collagenous and lymphocytic)
  • Eosinophilic esophagitis

Advanced gastroenterology therapies we deliver

TheraVite Health delivers and manages complex IBD biologics and immune-mediated GI therapies, including high-cost agents administered via infusion induction and subcutaneous maintenance.

Infusion therapies (in-suite administration)

  • Remicade (infliximab) and biosimilars (Inflectra, Renflexis, Avsola) — IV anti-TNF
  • Entyvio (vedolizumab) — IV anti-α4β7 integrin, gut-selective
  • Stelara (ustekinumab) and biosimilars — IV induction (followed by SC maintenance)
  • Skyrizi (risankizumab) — IV induction (followed by SC maintenance)

Subcutaneous therapies (specialty pharmacy dispensing)

  • Entyvio Pen (vedolizumab) — SC maintenance formulation
  • Stelara (ustekinumab) and biosimilars — SC maintenance
  • Skyrizi (risankizumab) — SC maintenance
  • Humira (adalimumab) and biosimilars — SC anti-TNF
  • Cimzia (certolizumab pegol) — SC anti-TNF
  • Tremfya (guselkumab) — SC IL-23 inhibitor
  • Omvoh (mirikizumab) — SC IL-23 inhibitor
  • Dupixent (dupilumab) — SC IL-4/13 inhibitor for eosinophilic esophagitis
TheraVite supports both administration (IV induction) and dispensing (SC maintenance), enabling seamless transitions across the IBD treatment continuum without changing pharmacies mid-therapy.

What makes TheraVite’s approach distinct

Inflammatory bowel disease often involves long sequences of biologic therapy as patients respond to or lose response to one drug class and transition to another. TheraVite’s integrated approach simplifies this for IBD patients: your IV induction (Remicade, Stelara IV, Entyvio IV) happens in our suite; your maintenance dosing transitions to our specialty pharmacy if you move to a SC formulation (Entyvio Pen, Stelara SC, Humira); and the same multidisciplinary care team coordinates your prior authorization across these transitions without requiring new patient onboarding each time you switch.

For referring providers

TheraVite handles prior authorization, benefits investigation, and payor credentialing for all therapies listed above. For drugs subject to limited distribution networks, we are pursuing manufacturer access in parallel with URAC accreditation. Contact us for current access status by drug.

Submit a referral →

For patients

If you have been prescribed any of the therapies above, TheraVite can typically begin treatment within 5 to 10 business days of receiving your prescription. We handle insurance verification, prior authorization, and patient onboarding so you can focus on your therapy.

Schedule an appointment →

Ready to get started?

Refer a Patient Schedule an Appointment